A Phase II open label study of IMMU-132 in metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1/ PD-L1 based immunotherapy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Urothelial Carcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients with histologically confirmed urothelial cancer of the renal pelvis, ureter, bladder or urethra. Both transitional cell and mixed transitional cell / non-transitional cell are allowed but transitional cell histology must be predominant. 2.

You may not be eligible for this study if the following are true:

  • 1. Has a diagnosis of immunodeficiency. 2. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study Day 1 or who has not recovered (i.e., < Grade 1 or at baseline) from adverse events due to agents administered more than 4 wee

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.